Western ALS Study Group.
Miller
R G
RG
Moore
D H
DH
Jackson
C E
CE
D000588:Amines / Q000627:therapeutic use; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D020934:Ciliary Neurotrophic Factor / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods*; D003299:Cooperative Behavior; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D008911:Minocycline / Q000627:therapeutic use; D012955:Societies, Medical / Q000458:organization & administration*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D002121:Calcium Channel Blockers; D020934:Ciliary Neurotrophic Factor; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D003520:Cyclophosphamide; D008911:Minocycline